Haemonetics Corp (HAE) Stock Price, Quote & News

Company Profile

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and s...

Industry: Medical Devices

Sector: Healthcare

Phone: 781 848 7100

Website: www.haemonetics.com

Address:

125 Summer Street, Boston, United States

anachartanalyst Jun. 17 at 10:01 AM

$HAE https://anachart.com/wp-content/uploads/2026/06/1781690468_soc-img.jpg

0 · Reply

IndyOne Jun. 12 at 8:56 PM

$HAE On my list, wanted to buy today but did not like the open, any catalysts coming?

0 · Reply

Cutlass Jun. 11 at 2:16 PM

$HAE Out for now 52 > 80 = 🤠

0 · Reply

Cutlass Jun. 8 at 4:07 PM

$HAE Looking to sell some 52's this week - ✍️

0 · Reply

NVDAMillionaire Jun. 5 at 6:32 PM

$HAE Excellent article that nails exactly where HAE stands right now. So if you want to update your HAE knowledge or get acquainted with HAE, this is a must read. https://everyticker.com/quote/HAE/analysis/margin-expansion-meets-plasma-innovation-haemonetics-medtech-transformation-nyse-hae

0 · Reply

Cutlass Jun. 4 at 7:24 PM

$HAE What a bounce off 52 😃 Holding -

0 · Reply

Linda1155 Jun. 2 at 12:13 AM

$HAE Revenue growth has been inconsistent, with several quarters showing declines or only low-single-digit growth.*

0 · Reply

Linda1155 Jun. 2 at 12:08 AM

$HAE

0 · Reply

d_risk May. 21 at 9:49 AM

$HAE - Haemonetics Corporation - 10K - Updated Risk Factors Risk shifts highlight new concentration (a single customer now 13% of net revenue), execution risk from a major global ERP rollout, added regulatory burden and uncertainty from FDA’s new QMSR and evolving Brexit/Swexit rules, plus clarified but still evolving global tax exposure despite OBBBA and G7 Pillar Two relief. #MedicalDevices #CustomerConcentration #ERPImplementationRisk #RegulatoryCompliance #GlobalTaxExposure 🟢 Added 🟠 Removed https://d-risk.ai/HAE/10-K/2026-05-20

0 · Reply

SuperGreenToday May. 20 at 12:52 AM

$HAE Share Price: $56.85 Contract Selected: Dec 18, 2026 $70 Calls Buy Zone: $1.66 – $2.05 Target Zone: $3.03 – $3.70 Potential Upside: 73% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Haemonetics management to meet virtually with BTIG

2026-06-15T11:14:38.000Z - 4 days ago

Haemonetics price target raised to $85 from $70 at Mizuho

Jun 11, 2026, 6:50 AM EDT - 8 days ago

Pharvaris Announces Annual General Meeting of Shareholders

PHVS

Jun 9, 2026, 8:00 AM EDT - 10 days ago

Haemonetics Proxy statement: Proxy filing

Jun 9, 2026, 8:00 AM EDT - 10 days ago

Haemonetics Proxy statement: Proxy filing

Jun 8, 2026, 4:00 PM EDT - 10 days ago

Haemonetics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 5, 2026, 6:30 AM EDT - 14 days ago

Haemonetics Updates Financial Reporting Segments

Jun 2, 2026, 4:05 PM EDT - 16 days ago

Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference

2026-05-28T12:18:27.000Z - 22 days ago

Haemonetics price target raised to $70 from $64 at Citi

2026-05-22T10:20:08.000Z - 4 weeks ago

Haemonetics upgraded to Buy at BofA on upside to guidance

2026-05-22T10:14:44.000Z - 4 weeks ago

Haemonetics upgraded to Buy from Neutral at BofA

May 12, 2026, 11:00 AM EDT - 5 weeks ago

Haemonetics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T11:46:56.000Z - 5 weeks ago

Haemonetics price target lowered to $89 from $94 at Barrington

2026-05-08T16:35:30.000Z - 6 weeks ago